CLOSED STUDIES / Ovarian Cancer


ICON-6 / GEICO-1101


Title

Gynaecologic Cancer Intergroup double-blind, controlled, multicenter clinical trial of Cediranib (AZD 2171), in combination either with platinum-based chemotherapy or as the sole agent in maintenance therapy, in women with ovarian cancer who have relapsed over 6 months after termination of a platinum-based first-line treatment.


GEICO Coordinator

Dr. Antonio Gonzalez Martin


GEICO Investigators

Dr. Antonio Casado. H. C. San Carlos
Dr. Belén Ojeda H. Sant Pau.
Dr. Ana Santaballa.H. U. La Fe
Dr. Andrés Redondo Sánchez. H.U La Paz
Dr. Andres Cervantes. C.U. Valencia
Dr. Isabel Bover. H. Son Llatzer
Dr. Ana Herrero.H. Miguel Servet
Dr. María Jesús Rubio. H.Reina Sofía
Dr. Jesus García Donas. H. Alcorcón
Dr. Ana de Juan. H. M Valdecilla
Dr. Miguel Beltran. ICO Girona
Dr. Helena García. Morales Meseguer
Dr. José Angel Arranz. H. G. U. Gregorio Marañon
Dr. Antonio Gonzalez Martín. MD Anderson


Patients Recruited

2


Inclusion Closing Date

December of 2011


Current State

Following